{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NESP+-+Novel+Erythropoiesis+Stimulating+Protein&page=2", "query": { "intervention": "NESP - Novel Erythropoiesis Stimulating Protein", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NESP+-+Novel+Erythropoiesis+Stimulating+Protein&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NESP+-+Novel+Erythropoiesis+Stimulating+Protein&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T06:01:53.735Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00598442", "title": "Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Renal Failure", "Chronic Kidney Disease", "Anemia" ], "interventions": [ { "name": "peginesatide", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affymax", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 493, "start_date": "2007-11", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Granada Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00598442" }, { "nct_id": "NCT06184867", "title": "Choices About Genetic Testing And Learning Your Risk With Smart Technology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer", "Breast Cancer", "Pancreas Cancer", "Colorectal Cancer", "Endometrial Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Relational Agent (RA)", "type": "BEHAVIORAL" }, { "name": "Enhanced Usual Care (EUC)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-09-26", "completion_date": "2025-06-26", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06184867" }, { "nct_id": "NCT01731405", "title": "Consumer Understanding and Use of Medication Guides", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Revised Medication Guide Formats" ], "interventions": [], "intervention_types": [], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2012-11", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2014-04-09", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01731405" }, { "nct_id": "NCT05340465", "title": "Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prematurity", "Iron-deficiency", "Iron Deficiency Anemia", "Iron Malabsorption" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Low Molecular Weight Iron Dextran", "type": "DRUG" }, { "name": "Ferumoxytol injection", "type": "DRUG" }, { "name": "Oral iron supplements", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "3 Days", "sex": "ALL", "summary": "Up to 3 Days" }, "enrollment_count": 120, "start_date": "2022-11-27", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05340465" }, { "nct_id": "NCT00752609", "title": "Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Peginesatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 102, "start_date": "2008-09", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2012-07-27", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 10, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Middlebury", "state": "Connecticut" }, { "city": "Lauderdale Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752609" }, { "nct_id": "NCT02876835", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 3872, "start_date": "2016-09-27", "completion_date": "2021-04-19", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 161, "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02876835" }, { "nct_id": "NCT02879305", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia", "Aspergillosis, Allergic Bronchopulmonary" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2964, "start_date": "2016-09-28", "completion_date": "2020-11-09", "has_results": true, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 126, "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879305" }, { "nct_id": "NCT00146562", "title": "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Stage I Breast Cancer", "Stage II Breast Cancer" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harold J. Burstein, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2003-07", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2023-08-02", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lowell", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00146562" }, { "nct_id": "NCT07096297", "title": "Luspatercept + Darbepoetin in MDS", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MDS (Myelodysplastic Syndrome)" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" }, { "name": "Darbeopoetin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-12-16", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Columbus, Ohio + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07096297" }, { "nct_id": "NCT00442702", "title": "A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Mircera", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2007-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2011-12-19", "last_synced_at": "2026-10-09T06:01:53.735Z", "location_count": 11, "location_summary": "Granada Hills, California • Lauderdale Lakes, Florida • Augusta, Georgia + 8 more", "locations": [ { "city": "Granada Hills", "state": "California" }, { "city": "Lauderdale Lakes", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Mineola", "state": "New York" }, { "city": "Orchard Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00442702" } ] }